Consensus Zai Lab Limited Börse Stuttgart

Stocks

1ZL

US98887Q1040

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 05:16:37 2026-06-12 EDT			5-day change	1st Jan Change
15.05 ^EUR	-0.99%		+2.01%	+2.70%

06-10	Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading	MT
06-09	Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment	MT

Evolution of the Average Target: Zai Lab Limited

Evolution of the Target Price: Zai Lab Limited

Changes in Analyst Recommendations: Zai Lab Limited

492bc8338798dd0712dbb84b61a63.XEu-tcpzuxtGnW4yArZtQDGnE6OrbO_psDpP0TrvWnk.aizh_qM95FEs0DZgRIJAD0TOXsmGB6e49HknhlOCKCFqOIz2hCDZSDb7Ow~7d00259a8a0f862cff34cbf4fead802a

Analysts' recommendations: Zai Lab Limited

01-07	UBS Initiates Zai Lab at Buy With $35 Price Target	MT
11-04	Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study	RE
11-04	Zai Lab Limited Announces Update on Amgen's Bemarituzumab Phase 1B/3 Fortuda-102 Study	CI
25-03-13	JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating	MT
25-03-03	BofA Securities Downgrades Zai Lab to Neutral	MT
24-07-12	JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating	MT
23-12-14	Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target	MT
23-10-26	Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating	MT
23-10-26	Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating	MT
23-08-10	Cantor Fitzgerald Initiates Coverage on Zai Lab With Overweight Rating, $70 Price Target	MT
23-06-12	BofA Adjusts Price Target on Zai Lab to $62.50 From $75, Maintains Buy Rating	MT
23-05-11	Citigroup Adjusts Price Target on Zai Lab to $130 From $138, Keeps Buy Rating	MT
23-03-16	JPMorgan Adjusts Price Target on Zai Lab to $70 From $79, Maintains Overweight Rating	MT
22-11-18	JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating	MT
22-11-11	Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating	MT
22-08-09	Citigroup Adjusts Zai Lab's Price Target to $199 From $193, Reiterates Buy Rating	MT
22-05-25	CSPC Pharma Shares Fall After Weaker 1Q Profit	DJ
22-05-12	Citigroup Adjusts Zai Lab Price Target to $193 From $198, Maintains Buy Rating	MT
22-05-11	SVB Securities Adjusts Zai Lab Price Target to $95 From $101, Maintains Outperform Rating	MT
22-05-06	Guggenheim Adjusts Price Target for Zai Lab to $85 From $134, Maintains Buy Rating	MT
22-04-21	SVB Leerink Adjusts Zai Lab Price Target to $101 From $102, Maintains Outperform Rating	MT
22-04-04	JPMorgan Lowers Zai Lab's Price Target to $112 From $136, Maintains Overweight Rating	MT
22-03-03	Analyst recommendations: Acushnet, Bristol-Myers Squibb, Intel, iQIYI, Polymetal...
22-03-02	SVB Leerink Adjusts Zai Lab Price Target to $102 From $194, Maintains Outperform Rating	MT
21-12-03	Citigroup Raises Price Target for Zai Lab to $231 From $217, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REGENERON PHARMACEUTICALS, INC.					+36.28%
	UCB					+6.82%
	SAMSUNG BIOLOGICS CO.,LTD.					+63%
	CSL LIMITED					+31.6%
	BIOGEN INC.					+10.34%
	INCYTE CORPORATION					+1.17%
	MODERNA, INC.					-12.77%
	INNOVENT BIOLOGICS, INC.					+61.17%
	SWEDISH ORPHAN BIOVITRUM AB					+7.59%
	Average					+22.80%
	Weighted average by Cap.					+24.86%